Bank of New York Mellon
FNCH

Bank of New York Mellon’s Finch Therapeutics Group, Inc. Common Stock FNCH Stock Holding History

Bank of New York Mellon’s Portfolio FNCH Stock Details FNCH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-835
Closed -$126K – 4740
2022
Q1 		$126K Sell
835
-18
-2% -$4.15K ﹤0.01% 4356
2021
Q4 		$255K Buy
853
+13
+2% +$4.99K ﹤0.01% 4164
2021
Q3 		$328K Buy
840
+329
+64% +$140K ﹤0.01% 4008
2021
Q2 		$215K Buy
+511
New +$221K ﹤0.01% 4082

Other funds holding FNCH

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
AMC
Avenir Management Company New York $43.8M AUM 101.91% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
LSAG
Lake Street Advisors Group Portsmouth, New Hampshire $2.17B AUM 16.99% 1-Year Est. Return
TA
TRB Advisors New York $146M AUM 3.71% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

Bank of New York Mellon's FNCH Position: Q2 2022 in Review

Bank of New York Mellon sold out of Finch Therapeutics Group, Inc. Common Stock (FNCH) in Q2 2022, closing a stake of 835 shares — an estimated $126K sold.

Bank of New York Mellon first reported a position in FNCH in Q2 2021 and held it in 4 quarters. The position peaked at $328K in Q3 2021. 46 funds tracked by Wall St. Rank hold FNCH as of Q2 2022.

  • Bank of New York Mellon reported no remaining Finch Therapeutics Group, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Bank of New York Mellon sold 835 Finch Therapeutics Group, Inc. Common Stock shares in Q2 2022, an estimated $126K.
  • Bank of New York Mellon first reported a position in Finch Therapeutics Group, Inc. Common Stock in Q2 2021 and held it in 4 quarters.
  • Bank of New York Mellon's Finch Therapeutics Group, Inc. Common Stock position peaked at $328K in Q3 2021.
  • 46 funds tracked by Wall St. Rank held Finch Therapeutics Group, Inc. Common Stock as of Q2 2022.

Based on Bank of New York Mellon's 13F filing for Q2 2022, filed 15 Aug 2022.